Meeting
2023 ASCO Genitourinary Cancers Symposium
Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.
Authors
Matthew I. Feng
City of Hope, Duarte, CA
Matthew I. Feng , Sweta R. Prajapati , Daniela V. Castro , Kyle O. Lee , Elyse H. Chan , Ishaan Sehgal , Jalen Patel , Anna O'Dell , Zeynep Busra Zengin , Xiaochen Li , Alex Chehrazi-Raffle , Nazli Dizman , Abhishek Tripathi , Adam Rock , Sandy Liu , Benjamin D. Mercier , Luis A Meza , Errol James Philip , Tanya B. Dorff , Sumanta Monty Pal
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Cancer Disparities
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 34)
DOI
10.1200/JCO.2023.41.6_suppl.34
Abstract #
34
Poster Bd #
A17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.
First Author: Daniela V. Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.
First Author: Yifu Shi
Poster
2024 ASCO Genitourinary Cancers Symposium
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.
First Author: Fengnian Zhao
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan